Association of the Primary Aldosteronism Severity Classification with Lateralization and Treatment Outcomes

Clicks: 1
ID: 319266
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #350 of 360 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 360 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
CONTEXT: The 2025 clinical guideline for primary aldosteronism (PA) recommends a diagnostic and therapeutic pathway stratified by lateralization risk. The PA severity classification (PASC) integrates biochemical and clinical features and is intended to inform graded recommendations for adrenal venous sampling (AVS). OBJECTIVE: We examined whether PASC is associated with AVS-defined lateralization and treatment outcomes. DESIGN: A retrospective multicenter cohort study. SETTING: Eight tertiary centers. PATIENTS: A total of 833 patients with PA who underwent AVS. PASC severity was classified as mild, moderate, or severe. MAIN OUTCOME MEASURES: We evaluated associations between severity, AVS-defined lateralization, and outcomes using the Primary Aldosteronism Surgical Outcome (PASO) and Primary Aldosteronism Medical Treatment Outcome (PAMO) criteria. RESULTS: Among 833 patients, 52 (6.1%), 563 (67.6%) and 218 (26.2%) had mild, moderate, and severe PA, respectively. Higher severity was associated with a stepwise increase in AVS-defined lateralizing PA (19.2%, 48.0%, and 76.1%, respectively; p < 0.001). In unilateral PA treated surgically, PASO clinical outcomes differed by severity (p = 0.002), with complete clinical success in 40.2% (moderate) and 31.3% (severe), and a marked increase in partial clinical success in severe disease (55.1%). PASO biochemical outcomes were similar across severity groups (p = 0.389). In bilateral PA treated medically, PAMO clinical outcomes varied by severity (p = 0.005), with complete clinical response decreasing from mild to severe disease (36.8%, 27.0%, and 8.8%), whereas biochemical outcomes were comparable (p = 0.993). CONCLUSIONS: PASC-defined severity correlated with AVS-defined lateralization. Greater severity was associated with lower rates of complete clinical success/response despite preserved biochemical outcomes, supporting a severity-informed framework to complement AVS in PA management.
Reference Key
openalex_W7166647850 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ju Hee Lee, Ha Young Kim, M W Park, A Ram Hong, Jeongmin Lee, Kyong Yeun Jung, Hyo‐Jeong Kim, Eu Jeong Ku, Seung Shin Park, Seung Hun Lee, Jung Hee Kim
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag259
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.